{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:08:15Z","timestamp":1788815295970,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019073","name":"Industrial Innovation Funds of Jilin Province of China","doi-asserted-by":"publisher","award":["20260202038NC"],"award-info":[{"award-number":["20260202038NC"]}],"id":[{"id":"10.13039\/501100019073","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32372960"],"award-info":[{"award-number":["32372960"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32402841"],"award-info":[{"award-number":["32402841"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bcp.2026.118339","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T06:18:24Z","timestamp":1786429104000},"page":"118339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["An engineered oncolytic parapoxvirus induces immunogenic tumor cell death and displays antitumor efficacy by enhancing T cell responses"],"prefix":"10.1016","volume":"253","author":[{"given":"Qi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizhu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanglin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengshi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6459-7932","authenticated-orcid":false,"given":"Jiyu","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2026.118339_b0005","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Kim","year":"2014","journal-title":"Trends Mol. Med."},{"issue":"9","key":"10.1016\/j.bcp.2026.118339_b0010","article-title":"Hallmarks of CD8(+) T cell dysfunction are established within hours of tumor antigen encounter before cell division","volume":"24","author":"Michael","year":"2023","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118339_b0015","article-title":"Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma","volume":"187","author":"Daniel","year":"2023","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bcp.2026.118339_b0020","article-title":"Immune escape mechanisms as a guide for cancer immunotherapy","volume":"21","author":"Gregory","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.118339_b0025","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Mikhail","year":"2018","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118339_b0030","article-title":"Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle","volume":"20","author":"Wan-Chen","year":"2019","journal-title":"Nat. Immunol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118339_b0035","article-title":"11 clinical trials that will shape medicine in 2022","volume":"27","author":"Carrie","year":"2021","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.118339_b0040","article-title":"Emerging systemic delivery strategies of oncolytic viruses: a key step toward cancer immunotherapy","volume":"15","author":"Weiyue","year":"2022","journal-title":"Nano Res."},{"issue":"138","key":"10.1016\/j.bcp.2026.118339_b0045","article-title":"Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients","volume":"4","author":"Robert","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.bcp.2026.118339_b0050","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bjc.6602494","article-title":"Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery","volume":"92","author":"Wang","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.118339_b0055","doi-asserted-by":"crossref","DOI":"10.1007\/s10096-012-1780-x","article-title":"Therapeutic immunomodulation using a virus\u2013the potential of inactivated orf virus","volume":"32","author":"Weber","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"3","key":"10.1016\/j.bcp.2026.118339_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/0378-1135(87)90077-0","article-title":"A qualitative and quantitative assessment of the humoral antibody response of the sheep to orf virus infection","volume":"15","author":"Mckeever","year":"1987","journal-title":"Vet. Microbiol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118339_b0065","article-title":"Orf virus-based vaccine vector D1701-V induces strong CD8+ T cell response against the transgene but not against ORFV-derived epitopes","volume":"8","author":"Alena","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.bcp.2026.118339_b0070","article-title":"Novel chimeric parapoxvirus CF189 as an oncolytic immunotherapy in triple-negative breast cancer","volume":"163","author":"Audrey","year":"2017","journal-title":"Surgery"},{"issue":"15","key":"10.1016\/j.bcp.2026.118339_b0075","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00398-20","article-title":"Orf virus-based therapeutic vaccine for treatment of papillomavirus-induced tumors","volume":"94","author":"Schneider","year":"2020","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118339_b0080","article-title":"Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity","volume":"14","author":"Jing","year":"2023","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.bcp.2026.118339_b0085","article-title":"Orf virus ORF120 protein positively regulates the NF-\u03baB pathway by interacting with G3BP1","volume":"95","author":"Yanlong","year":"2021","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118339_b0090","article-title":"ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic","volume":"20","author":"Julia","year":"2012","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.118339_b0095","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s43657-023-00133-x","article-title":"Investigating the immunogenic cell death-dependent subtypes and prognostic signature of triple-negative breast cancer","volume":"4","author":"Shi","year":"2024","journal-title":"Phenomics"},{"issue":"3","key":"10.1016\/j.bcp.2026.118339_b0100","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s43657-023-00140-y","article-title":"Synergistically augmenting cancer immunotherapy by physical manipulation of pyroptosis induction","volume":"4","author":"Zhao","year":"2024","journal-title":"Phenomics"},{"issue":"602","key":"10.1016\/j.bcp.2026.118339_b0105","article-title":"Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade","volume":"13","author":"Ravi","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118339_b0110","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Lorenzo","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2026.118339_b0115","article-title":"Targeting tumor vasculature with an oncolytic virus","volume":"19","author":"Caroline","year":"2011","journal-title":"Mol. Ther."},{"issue":"13","key":"10.1016\/j.bcp.2026.118339_b0120","article-title":"Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication","volume":"15","author":"Robin","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.118339_b0125","article-title":"Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application","volume":"31","author":"Leonidas","year":"2007","journal-title":"Int. J. Oncol."},{"issue":"725","key":"10.1016\/j.bcp.2026.118339_b0130","article-title":"Orf virus infection of workers in the meat industry","volume":"96","author":"Robinson","year":"1983","journal-title":"N. Z. Med. J."},{"issue":"11","key":"10.1016\/j.bcp.2026.118339_b0135","article-title":"Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors","volume":"41","author":"Mieke","year":"2003","journal-title":"J. Clin. Microbiol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118339_b0140","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.10.6.1231-1235.1972","article-title":"The glycoprotein of vesicular stomatitis virus is the antigen that gives rise to and reacts with neutralizing antibody","volume":"10","author":"Kelley","year":"1972","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118339_b0145","article-title":"IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction","volume":"15","author":"Bana","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118339_b0150","article-title":"A tumor-conditional IL-15 safely synergizes with immunotherapy to enhance antitumor immune responses","volume":"32","author":"Wenqiang","year":"2024","journal-title":"Mol. Ther."},{"issue":"8047","key":"10.1016\/j.bcp.2026.118339_b0155","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"David","year":"2024","journal-title":"Nature"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:19:55Z","timestamp":1788812395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226006787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":31,"alternative-id":["S0006295226006787"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118339","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An engineered oncolytic parapoxvirus induces immunogenic tumor cell death and displays antitumor efficacy by enhancing T cell responses","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118339","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118339"}}